Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company

SCG Cell Therapy Launches Global Manufacturing and R&D Center in Singapore with Automated System

Fineline Cube Jul 21, 2023

Singapore-based SCG Cell Therapy Pte. Ltd has announced the initiation of its global manufacturing and...

Company Deals

Zennova Pharmaceutical Group Secures RMB 100 Million in Series B Financing for Commercial Manufacturing and R&D

Fineline Cube Jul 21, 2023

China-based Zennova Pharmaceutical Group has reportedly raised close to RMB 100 million (USD 13.9 million)...

Company Drug

Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review

Fineline Cube Jul 21, 2023

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation...

Company Legal / IP

Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent

Fineline Cube Jul 21, 2023

The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and...

Company Drug

Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices

Fineline Cube Jul 21, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter...

Company

Sartorius Expands Global Footprint with New Cell Culture Facility in Puerto Rico

Fineline Cube Jul 21, 2023

Germany-based laboratory services firm Sartorius has expanded its operations with the opening of a new...

Company

Sandoz Plans USD 90 Million Biosimilar Development Center in Slovenia by 2026

Fineline Cube Jul 21, 2023

The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar...

Company Deals Policy / Regulatory

Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority

Fineline Cube Jul 21, 2023

United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging...

Company Deals

GSK Partners with LimmaTech for Further Development of Quadrivalent Shigellosis Vaccine

Fineline Cube Jul 21, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate...

Company

Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip

Fineline Cube Jul 21, 2023

US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug

Fineline Cube Jul 21, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...

Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China

Fineline Cube Jul 21, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese...

Company Deals Digital

Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services

Fineline Cube Jul 20, 2023

China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with...

Drug

Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study

Fineline Cube Jul 20, 2023

Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...

Legal / IP Policy / Regulatory

US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes

Fineline Cube Jul 20, 2023

The United States has published an update to its merger and acquisition guidelines, seeking public...

Company Drug

Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy

Fineline Cube Jul 20, 2023

A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...

Company Drug

Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB

Fineline Cube Jul 20, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...

Company Drug

Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine

Fineline Cube Jul 20, 2023

Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...

Company Drug

Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China

Fineline Cube Jul 20, 2023

The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...

Company Drug

HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer

Fineline Cube Jul 20, 2023

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...

Posts pagination

1 … 434 435 436 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.